HK1144915A1 - Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis 24-c- - Google Patents

Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis 24-c-

Info

Publication number
HK1144915A1
HK1144915A1 HK10111591.8A HK10111591A HK1144915A1 HK 1144915 A1 HK1144915 A1 HK 1144915A1 HK 10111591 A HK10111591 A HK 10111591A HK 1144915 A1 HK1144915 A1 HK 1144915A1
Authority
HK
Hong Kong
Prior art keywords
leishmaniasis
methyltransferase
diagnosis
prevention
compositions
Prior art date
Application number
HK10111591.8A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文‧里德
后藤康之
Original Assignee
傳染性疾病研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 傳染性疾病研究院 filed Critical 傳染性疾病研究院
Publication of HK1144915A1 publication Critical patent/HK1144915A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
HK10111591.8A 2007-07-13 2010-12-13 Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis 24-c- HK1144915A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94963707P 2007-07-13 2007-07-13
PCT/US2008/069843 WO2009012166A1 (fr) 2007-07-13 2008-07-11 Compositions de stérol 24-c-méthyltransférase de leishmania pour la prévention, le traitement et le diagnostic de leishmanioses

Publications (1)

Publication Number Publication Date
HK1144915A1 true HK1144915A1 (en) 2011-03-18

Family

ID=39760688

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111591.8A HK1144915A1 (en) 2007-07-13 2010-12-13 Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis 24-c-

Country Status (7)

Country Link
US (1) US8916168B2 (fr)
EP (1) EP2170372A1 (fr)
CN (1) CN101743016B (fr)
BR (1) BRPI0815565A2 (fr)
EA (1) EA017958B1 (fr)
HK (1) HK1144915A1 (fr)
WO (1) WO2009012166A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833534B2 (en) 2006-04-10 2010-11-16 Infectious Disease Research Institute Compounds and methods for diagnosis and treatment of leishmaniasis
US8410258B2 (en) 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
AR073170A1 (es) * 2008-05-21 2010-10-20 Infectious Disease Res Inst Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis
ES2628743T3 (es) 2008-07-03 2017-08-03 Infectious Disease Research Institute Proteínas de fusión y su uso en el diagnóstico y tratamiento de la leishmaniasis
ES2352780B2 (es) * 2009-06-04 2011-09-15 Laboratorios Ovejero S.A. Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
WO2012064659A1 (fr) * 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccins comprenant des polypeptides d'hydrolase nucléosidique et de stérol 24-c-méthyltransférase (smt) non spécifiques destinés à traiter et à diagnostiquer la leishmaniose
BR112015024860B1 (pt) 2013-03-28 2023-11-07 Access To Advanced Health Institute Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
MX2018014399A (es) 2016-06-01 2019-06-06 Infectious Disease Res Inst Particulas de nanoalumbre que contienen un agente de dimensionamiento.
CA3141577A1 (fr) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
CN117120087A (zh) 2020-12-23 2023-11-24 高级健康研究所 茄尼醇疫苗助剂及其制备方法
CN114250206B (zh) * 2021-12-25 2024-03-19 苏州瀚源新酶生物科技有限公司 甲基转移酶突变体、重组载体、重组工程菌及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500437B1 (en) * 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Also Published As

Publication number Publication date
CN101743016B (zh) 2015-05-13
US8916168B2 (en) 2014-12-23
BRPI0815565A2 (pt) 2015-02-18
EA201070140A1 (ru) 2010-08-30
WO2009012166A1 (fr) 2009-01-22
US20090041798A1 (en) 2009-02-12
EA017958B1 (ru) 2013-04-30
CN101743016A (zh) 2010-06-16
EP2170372A1 (fr) 2010-04-07

Similar Documents

Publication Publication Date Title
HK1144915A1 (en) Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis 24-c-
HK1202558A1 (en) Compositions and methods for the therapy and diagnosis of influenza
EP2212440A4 (fr) Procédés et compositions destinés au diagnostic et au traitement de l'adénocarcinome de l' sophage
IL249165A0 (en) Use of an antigen-mhc complex to prepare drugs for the prevention and treatment of autoimmune conditions
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
EP2129683A4 (fr) Procedes et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles
IL184312A0 (en) Herbal compositions for the treatment of diabetes and/or conditions associated therewith
EP1969147A4 (fr) Méthodes et compositions basées sur des micro-arn et s'appliquant au diagnostic et au traitement de cancers solides
EP2201370A4 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
IL212651A (en) Preparations for the treatment of acute lymphoblastic leukemia in children
EP2361089A4 (fr) Compositions et procédés pour le traitement d une fonction altérée de l' -synucléine
EP2097012A4 (fr) Dispositifs et procédés pour le traitement d'une insuffisance cardiaque
IL193297A0 (en) Imidazole-based compounds, compositions comprising them and methods of their use
ZA200900388B (en) Compositions and methods for the treatment of mucositis
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
PL2086642T3 (pl) DNaza do leczenia męskiej subpłodności
GB0718446D0 (en) Compositions and methods for the treatment of infection
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
ZA201101278B (en) Compounds,compositions and methods for the treatment of b-amyloid diseases and synucleinopathies
EP2217238A4 (fr) Procédés et compositions pour le traitement de maladies protéinuriques
EP2209458A4 (fr) Compositions de traitement de la peau
GB0909297D0 (en) Composition for the treatment of skin conditions
ZA200808363B (en) Compounds and methods for diagnosis and treatment of leishmaniasis
EP2231146A4 (fr) Composition pharmaceutique pour le traitement et la prévention du glaucome
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia